CME Credit Hours: 1.25
Colorectal cancer always has a genetic etiology, with at least 5% of cases due to germline mutations, and even patients with sporadic cancers due to somatic gene mutations demonstrating genetic alterations in the tumor that may guide their treatment. While patients with certain types of colorectal cancer may benefit from immunotherapy and other novel and new treatments, those patients with hereditary colorectal cancer syndromes require complex decision-making regarding their care, including deciding on the best surgical options in their management.
Objectives
At the conclusion of this session, participants should be able to:
- Describe the surgical options for patients with Lynch Syndrome and explain when each is appropriate
- Recognize the importance of genetic testing as well as phenotype in surgical decision-making for patients with polyposis syndromes
- Classify tumors (and treatments) by genetic alterations for both sporadic and hereditary colorectal cancer patients
- Discuss the role of immunotherapy in the treatment of colorectal cancer
Co-Directors
Emily Steinhagen, MD, Cleveland, OH
Paul Wise, MD, St. Louis, MO
Introduction and Opening Comments
Emily Steinhagen, MD, Cleveland, OH
Paul Wise, MD, St. Louis, MO
When in Doubt, Take it Out? Extent of Surgery in Lynch Syndrome
Sonia Ramamoorthy, MD, San Diego, CA
Gene-mutation Negative Polyposis: Now What?
James Church, MD, Cleveland, OH
What is the Tumor Telling Us? A Primer in Tumor Profiling
Heather Hampel, MS, LGC, Columbus, OH
Immunotherapy: When & For Whom?
Aaron Miller, MD, PhD, San Diego, CA
Panel Discussion and Questions
Adjourn